| Brand Name | Palnat 125 |
| Packaging Type | Bottle |
| Molecule | Palbociclib |
| Generic Name | Palbociclib 125mg |
| Manufactured By | Natco Pharma |
| Quantity | 21 Capsules |
| Form | Capsule |
| Country of Origin | India |
| Categories | Oncology |
Introduction to Palnat Palbociclib 125mg
Palnat Palbociclib 125mg is an important drug in the fight against breast cancer. It specifically targets hormone receptor-positive, HER2-negative breast cancer. Palnat helps by blocking cancer cells from dividing and multiplying, which slows down or stops the disease's progression.
Palnat 125mg Capsule helps by stopping cancer cells from dividing and spreading, slowing down the disease. As a generic version of Ibrance, Palnat provides the same benefits at a lower cost, making it more accessible for patients needing long-term treatment. This availability offers a vital option for many, ensuring effective treatment is reachable for more people.
Palnat is crucial in treating a common and tough form of breast cancer, giving patients an affordable and targeted therapy option.
Definition and Role of Palbociclib
Palbociclib is the main ingredient in Palnat Capsules. It blocks the certain enzymes called CDK4 and CDK6. These enzymes are important for cancer cell growth. By blocking them, Palbociclib slows down the cancer’s cell growth.
How Palbociclib Works?
Palbociclib stops the activity of CDK4 and CDK6, which are proteins that help cells divide. In cancer cells, these proteins can become too active, causing uncontrolled growth. By inhibiting CDK4 and CDK6, Palnat prevents cancer cells from dividing and leads them to die. This method effectively manages hormone receptor-positive breast cancer.
Palbociclib specifically treats hormone receptor-positive, HER2-negative advanced breast cancer. This cancer type has tumors that respond to hormones like estrogen but do not produce excess HER2 protein. Palnat helps control the growth of these hormone-sensitive tumors, improving patient outcomes and extending disease control.
Palbociclib FDA Approval
On February 31, 2017, the FDA granted regular approval for palbociclib, the active component in Palnat 125mg. It is used to treat advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). It is prescribed with an aromatase inhibitor or fulvestrant.
The FDA approved palbociclib based on the PALOMA-1 clinical trial, which showed that combining palbociclib with letrozole improved progression-free survival in postmenopausal women compared to letrozole alone. This led to a fast-track approval under the Breakthrough Therapy designation because of its significant benefits for patients.
Dosage and Administration
Standard Dosage for Palnat 125mg Capsules
Take 125 mg of Palnat (Palbociclib 125mg) Capsule once daily for 21 days in a 28-day cycle, usually with other hormone therapies.
Proper Administration Instructions
- Take at the same time each day.
- Swallow whole with a glass of water. Do not crush or chew.
- Can be taken with or without food.
Adjustments Based on Patient Needs
- Dose Adjustments: Adjustments may be needed based on liver function or side effects.
- Hepatic Impairment: May require a reduced dose for liver issues.
Guidelines for Missed Dose or Overdose
- Missed Dose: Take as soon as remembered, or skip if close to the next dose.
- Overdose: Seek immediate medical attention and contact a healthcare provider.
- Always follow your doctor's instructions for proper usage and dosage adjustments.
Storage Instruction for Palnat 125mg
- Keep Palnat at room temperature, between 20°C to 25°C (68°F to 77°F).
- Store the medication in a dry place, away from moisture and humidity. Do not store in the bathroom.
- Keep the medication in its original container with the lid tightly closed to protect it from light and moisture.
- Store Palnat in a secure place out of the reach of children and pets.
- Check the expiry date on the packaging and do not use the medication past this date.
Palbociclib Side effect
Side effects are unwanted symptoms that can occur with medications. While most medicines can cause side effects, not everyone will experience them.
Common side effect
- Tiredness
- Hair loss
- Dry skin, rash
- Infections
- Low blood cell counts
- Decreased of appetite
- Nausea, vomiting
- Diarrhea
- Swelling of lips and mouth
- Changes in taste
- Nose bleed
- Dry eye, blurred vision, increased tearing
Serious:
- Blood disorder (fever, chills, shortness of breath, weakness, bleeding, or bruising)
- Lung inflammation (chest pain, dry cough, or difficulty breathing)
Precautions while taking Palnat 125mg
Avoid Pregnancy:- Palbociclib can harm an unborn baby. Use reliable birth control during treatment and for at least three weeks after your last dose.
Infection Risk: Palbociclib may lower your white blood cell count, raising your risk of infection. Tell your doctor if you notice any signs of infection, like fever or a sore throat.
Liver Function Monitoring: You need regular liver tests during treatment to check for problems.
Limit Alcohol Consumption:Drinking alcohol can worsen side effects, especially liver issues.
Avoid Grapefruit: Grapefruit and its juice can interact with Palbociclib and increase side effects.
Approval
https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance
Palnat vs. Ibrance
Comparative Overview: Palnat vs. Ibrance
| Feature | Palnat (Palbociclib 125mg) | Ibrance (Palbociclib 125mg) |
| Active Ingredient | Palbociclib | Palbociclib |
| Manufacturer | Natco Pharma | Pfizer |
| FDA Approval | Equivalent to Ibrance, not independently FDA-approved | FDA-approved (2017) |
| Indication | HR+/HER2- Advanced or Metastatic Breast Cancer | HR+/HER2- Advanced or Metastatic Breast Cancer |
| Mechanism of Action | CDK4/6 Inhibitor | CDK4/6 Inhibitor |
| Pricing | $178 (apx) | $17,000 (apx) |
| Availability | May vary based on country or region | Widely available globally through Pfizer |
| Combination Therapy | Combined with Aromatase Inhibitors or Fulvestrant | Combined with Aromatase Inhibitors or Fulvestrant |
| Efficacy | Comparable to Ibrance in clinical usage | Proven efficacy in clinical trials (PALOMA series) |
Palnat 125 mg is used to treat certain types of breast cancer by slowing the growth of cancer cells.
The price of Palnat 125 mg capsules in India varies by pharmacy and location. It typically costs about $170 to $200 for a month's supply.
Palbociclib is not traditional chemotherapy. It is a targeted therapy that blocks specific proteins (CDK4 and CDK6) that help cancer cells grow.
Palbociclib is a targeted therapy drug known as a CDK4/6 inhibitor. It targets proteins involved in cancer cell division to help control growth.
Life expectancy for patients using Palbociclib varies widely based on cancer type, stage, overall health, and response to the drug. Discussing this with a healthcare provider can give a personalized outlook.
